April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
De-Aggregation of Soluble CD44 Prevents Cytotoxicity
Author Affiliations & Notes
  • R. M. Beverley
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • R. D. McCarty
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • M. C. Giovingo
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • M. J. Nolan
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • J. R. Samples
    Casey Eye Institute, Portland, Oregon
  • B. Y. J. T. Yue
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • P. A. Knepper
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
    Department of Ophthalmology, Northwestern University, Chicago, Illinois
  • Footnotes
    Commercial Relationships  R.M. Beverley, None; R.D. McCarty, None; M.C. Giovingo, None; M.J. Nolan, None; J.R. Samples, None; B.Y.J.T. Yue, None; P.A. Knepper, Alcon, R.
  • Footnotes
    Support  Alcon Research Ltd
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3203. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. M. Beverley, R. D. McCarty, M. C. Giovingo, M. J. Nolan, J. R. Samples, B. Y. J. T. Yue, P. A. Knepper; De-Aggregation of Soluble CD44 Prevents Cytotoxicity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3203.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Recent evidence suggests that destabilized protein aggregates are toxic in a variety of neurodegenerative diseases. Our laboratory has identified soluble CD44 (sCD44), the shed extracellular domain of membrane CD44, as a toxic protein which may be a causative factor in primary open-angle glaucoma (POAG). This study examined whether the aggregated form of sCD44 is more toxic to trabecular meshwork (TM) cells than a de-aggregated preparation.

Methods: : sCD44 was isolated from human serum by sequential anion exchange, hyaluronic acid affinity chromatography and immunoprecipitation. A de-aggregated sCD44 preparation was obtained by dialysis through a 50 kDa cut-off membrane which was chosen to ensure that the released proteins were monomeric. Aliquots of each preparation were followed by a thioflavin T binding fluorescence assay to measure the extent of aggregation. Blue native polyacrylamide gel electrophoresis (BNPAGE) and Western blot analysis using A11 (a beta-sheet specific antibody), serum amyloid A and CD44 antibodies were also performed to examine the extent of aggregation of each preparation. Human TM cells incubated with 1, 5 and 10 ng/ml aggregated sCD44, de-aggregated sCD44, heat-inactivated sCD44 (negative control) and 5 and 50 ug/ml amyloid beta [1-42] (positive control) were tested for cell survival after 24 hours.

Results: : sCD44 formed extremely large aggregates and displayed a beta amyloid-like oligomer conformation by BNPAGE analysis using A11, a beta-sheet specific antibody. De-aggregation of sCD44 occurred in three days as determined by a thioflavin T fluorescence assay and BNPAGE. The sCD44 amyloid-like aggregates were toxic and decreased cell viability (P<0.005), whereas the freshly de-aggregated sCD44 preparation was non-toxic in a bioassay of cell toxicity using primary TM cells. After storage for 24 days, the de-aggregated sCD44 preparation was re-tested; sCD44 had re-aggregated by BNPAGE and regained toxicity toward TM cells.

Conclusions: : Our results suggest that the extent of sCD44 aggregation predicates its cytotoxicity. Preventing aggregation and/or de-aggregating the toxic proteins may prove to be an effective treatment in neurodegenerative diseases such as POAG.

Keywords: trabecular meshwork • apoptosis/cell death • cell survival 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×